Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,050 Average Price Target from Analysts

Shares of Hikma Pharmaceuticals PLC (LON:HIKGet Free Report) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is GBX 2,225 ($28.23).

Several equities analysts have issued reports on HIK shares. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 ($25.37) price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Barclays reiterated an “equal weight” rating and set a GBX 2,000 ($25.37) target price on shares of Hikma Pharmaceuticals in a research note on Tuesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 2,750 ($34.89) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, June 18th.

Get Our Latest Stock Analysis on Hikma Pharmaceuticals

Hikma Pharmaceuticals Stock Performance

LON HIK opened at GBX 1,983 ($25.16) on Tuesday. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27. Hikma Pharmaceuticals has a 1 year low of GBX 1,711 ($21.70) and a 1 year high of GBX 2,222 ($28.19). The company has a market capitalization of £4.40 billion, a PE ratio of 2,953.73, a P/E/G ratio of 2.38 and a beta of 0.44. The company has a fifty day moving average of GBX 1,936.95 and a two-hundred day moving average of GBX 1,902.10.

Insider Buying and Selling at Hikma Pharmaceuticals

In related news, insider Riad Mishlawi bought 736 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was bought at an average cost of GBX 1,979 ($25.10) per share, with a total value of £14,565.44 ($18,477.03). 30.62% of the stock is currently owned by corporate insiders.

About Hikma Pharmaceuticals

(Get Free Report

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

Recommended Stories

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.